JP2010501172A5 - - Google Patents

Download PDF

Info

Publication number
JP2010501172A5
JP2010501172A5 JP2009525261A JP2009525261A JP2010501172A5 JP 2010501172 A5 JP2010501172 A5 JP 2010501172A5 JP 2009525261 A JP2009525261 A JP 2009525261A JP 2009525261 A JP2009525261 A JP 2009525261A JP 2010501172 A5 JP2010501172 A5 JP 2010501172A5
Authority
JP
Japan
Prior art keywords
nptx1
level
fgfr1op
cells
lung cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009525261A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010501172A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2007/066825 external-priority patent/WO2008023840A2/en
Publication of JP2010501172A publication Critical patent/JP2010501172A/ja
Publication of JP2010501172A5 publication Critical patent/JP2010501172A5/ja
Pending legal-status Critical Current

Links

JP2009525261A 2006-08-25 2007-08-23 肺癌に対する予後マーカーおよび治療標的 Pending JP2010501172A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84037606P 2006-08-25 2006-08-25
US89480107P 2007-03-14 2007-03-14
PCT/JP2007/066825 WO2008023840A2 (en) 2006-08-25 2007-08-23 Prognostic markers and therapeutic targets for lung cancer

Publications (2)

Publication Number Publication Date
JP2010501172A JP2010501172A (ja) 2010-01-21
JP2010501172A5 true JP2010501172A5 (cg-RX-API-DMAC7.html) 2011-09-29

Family

ID=38669227

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009525261A Pending JP2010501172A (ja) 2006-08-25 2007-08-23 肺癌に対する予後マーカーおよび治療標的

Country Status (4)

Country Link
US (1) US20100292090A1 (cg-RX-API-DMAC7.html)
EP (3) EP2423332A1 (cg-RX-API-DMAC7.html)
JP (1) JP2010501172A (cg-RX-API-DMAC7.html)
WO (1) WO2008023840A2 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
US20070231872A1 (en) 2004-07-27 2007-10-04 Nativis, Inc. System and Method for Collecting, Storing, Processing, Transmitting and Presenting Very Low Amplitude Signals
JP2009502115A (ja) * 2005-07-27 2009-01-29 オンコセラピー・サイエンス株式会社 小細胞肺癌の診断方法
US20110152345A1 (en) * 2007-08-24 2011-06-23 Oncotherapy Science, Inc. Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis
CA2734979A1 (en) * 2008-08-27 2010-03-04 Oncotherapy Science, Inc. Syngr4 for target genes of cancer therapy and diagnosis
WO2010117349A1 (en) * 2009-04-08 2010-10-14 Nativis, Inc. Time-domain transduction signals and methods of their production and use
US20130165734A1 (en) * 2009-04-08 2013-06-27 Nativis, Inc. Time-domain transduction signals and methods of their production and use
CN105586433A (zh) * 2009-10-26 2016-05-18 雅培制药有限公司 用于测定非小细胞肺癌预后的诊断方法
WO2011083830A1 (ja) * 2010-01-06 2011-07-14 学校法人関西文理総合学園 新規抗がん剤およびそのスクリーニング方法
EP2968967A4 (en) 2013-03-15 2016-08-17 Nativis Inc CONTROL AND FLEXIBLE COILS FOR THERAPY ADMINISTRATION, SUCH AS CANCER THERAPY
CN108117590A (zh) * 2016-11-30 2018-06-05 天津师范大学 一种特异性抗Kif4A蛋白1161位苏氨酸磷酸化抗体的制备方法与应用
KR102177269B1 (ko) * 2019-04-19 2020-11-10 충남대학교 산학협력단 뇌종양 진단 또는 예후 예측용 바이오마커 조성물
CN115461475A (zh) * 2019-12-02 2022-12-09 达特茅斯学院理事会 Myc癌基因的靶向mb2及其与癌症中的trrap的相互作用

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
GB1499026A (en) 1975-06-20 1978-01-25 Farmaceutici Italia Adriamycin esters
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
EP0349578B2 (en) 1987-03-02 1998-10-28 Enzon Labs Inc. Organism carrying a Single Chain Antibody Domain at its surface.
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
AU641673B2 (en) 1989-06-29 1993-09-30 Medarex, Inc. Bispecific reagents for aids therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ATE295420T1 (de) 1992-02-06 2005-05-15 Chiron Corp Marker für krebs und biosynthetisches bindeprotein dafür
EP0626012B1 (en) 1992-02-11 2003-07-09 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
WO1994004690A1 (en) 1992-08-17 1994-03-03 Genentech, Inc. Bispecific immunoadhesins
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
JP3479100B2 (ja) 1993-06-02 2003-12-15 帝国臓器製薬株式会社 免疫化学的簡易半定量方法および装置
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
ID27813A (id) * 1998-01-28 2001-04-26 Corixa Corp Senyawa-senyawa untuk terapi dan diagnosa kanker paru-paru dan metoda untuk penggunaannya
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
WO2001077168A2 (en) * 2000-04-11 2001-10-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030194764A1 (en) * 2001-04-05 2003-10-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
WO2002088171A2 (en) 2001-04-26 2002-11-07 Avidia Research Institute Combinatorial libraries of monomer domains
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
KR100990055B1 (ko) 2001-11-21 2010-10-26 사이고 가오루 유전자 발현 억제 방법
EP1466016A2 (en) * 2002-01-09 2004-10-13 Riken Institute Of Physical And Chemical Research Cancer profiles
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US20050106160A1 (en) 2002-03-05 2005-05-19 Dimitrov Dimiter S. Hiv-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and immunogens
EP1556402B1 (en) 2002-09-25 2011-06-22 University of Massachusetts In vivo gene silencing by chemically modified and stable sirna
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
WO2004063355A2 (en) * 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
WO2005044976A2 (en) 2003-06-20 2005-05-19 Isis Pharmaceuticals, Inc. Oligomeric compounds for use in gene modulation
US20050136437A1 (en) 2003-08-25 2005-06-23 Nastech Pharmaceutical Company Inc. Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
WO2005045037A2 (en) 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7700573B2 (en) 2004-03-23 2010-04-20 Oncotherapy Science, Inc. Method for diagnosing non-small lung cancer
EP1730534A2 (en) 2004-03-24 2006-12-13 Oncotherapy Science, Inc. Compositions and methods for treating lung cancer
EP2298892A3 (en) 2004-08-23 2011-11-16 Sylentis S.A.U. Treatment of eye disorders characterized by an elevated intraocular pressure by siRNAs
DE102004042822A1 (de) * 2004-08-31 2006-03-16 Technische Universität Dresden Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen
US20090163406A1 (en) * 2004-09-30 2009-06-25 The Regents Of The University Of California Compositions and methods for diagnosing and treating brain cancer and identifying neural stem cells
US20060252057A1 (en) * 2004-11-30 2006-11-09 Mitch Raponi Lung cancer prognostics
JP2009502115A (ja) * 2005-07-27 2009-01-29 オンコセラピー・サイエンス株式会社 小細胞肺癌の診断方法
TWI552751B (zh) 2011-06-20 2016-10-11 Ｈ 朗德貝克公司 投予４－（（１ｒ，３ｓ）－６－氯－３－苯基－二氫茚－１－基）－１，２，２－三甲基－哌及其鹽用於治療精神分裂症的方法

Similar Documents

Publication Publication Date Title
JP2010501172A5 (cg-RX-API-DMAC7.html)
Zhao et al. The lncRNA MACC1-AS1 promotes gastric cancer cell metabolic plasticity via AMPK/Lin28 mediated mRNA stability of MACC1
Zhang et al. Circular RNA CircCACTIN promotes gastric cancer progression by sponging MiR-331-3p and regulating TGFBR1 expression
Shi et al. LncRNA GLTC targets LDHA for succinylation and enzymatic activity to promote progression and radioiodine resistance in papillary thyroid cancer
Rong et al. Circular RNA CircEYA3 induces energy production to promote pancreatic ductal adenocarcinoma progression through the miR-1294/c-Myc axis
Zeng et al. Inhibition of STAT5a by Naa10p contributes to decreased breast cancer metastasis
Shi et al. ARRDC1 and ARRDC3 act as tumor suppressors in renal cell carcinoma by facilitating YAP1 degradation
Aryee et al. Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro
US20110152345A1 (en) Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis
Deng et al. ZHX3 promotes the progression of urothelial carcinoma of the bladder via repressing of RGS2 and is a novel substrate of TRIM21
JP2012511305A (ja) 癌の治療および診断の標的遺伝子としてのネクチン−４
US20110263012A1 (en) Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
Zhong et al. Long non‐coding RNA myocardial infarction associated transcript promotes epithelial‐mesenchymal transition and is an independent risk factor for poor prognosis of tongue squamous cell carcinoma
Topalov et al. Actin beta-like 2 as a new mediator of proliferation and migration in epithelial ovarian cancer
Shen et al. miR-34c-5p mediates the cellular malignant behaviors of oral squamous cell carcinoma through targeted binding of TRIM29
Cui et al. Ring finger protein 152 inhibits colorectal cancer cell growth and is a novel prognostic biomarker
US20110014615A1 (en) METHOD FOR DIAGNOSING NON-SMALL CELL LUNG CANCERS BY tRNA-DIHYDROURIDINE SYNTHASE ACTIVITY OF URLC8
Hashida et al. Significance of a calcium-binding protein S100A14 expression in colon cancer progression
Han et al. HOXB9 promotes osteosarcoma cell survival and malignancy under glucose starvation via upregulating SPP1 expression
US20110070245A1 (en) Imp-1 oncogene as a therapeutic target and prognostic indicator for lung cancer
KR20110063490A (ko) 암 치료 및 진단의 표적 유전자인 ｓｙｎｇｒ４
Ishii et al. Proteomic signatures corresponding to the SS18/SSX fusion gene in synovial sarcoma
WO2009113295A1 (en) C2orf18 as target gene for cancer therapy and diagnosis
Gong et al. Acetylation of Smad1 promotes tumorigenesis and chemoresistance via competitive attenuation of p300-mediated p53 acetylation in glioblastoma
Yang et al. Asparaginase Like 1 Predicts Unfavourable Prognosis and Facilitates Gastric Cancer Progression Through Inhibits GSK3-β